Bridgeway Capital Management, LLC Taysha Gene Therapies, Inc. Transaction History

Bridgeway Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.65 - $2.3 $33,430 - $118,291	51,431 Added 49.04%	156,300 $125,000
Q4 2022 Feb 14, 2023	SELL	$1.39 - $2.98 $48,650 - $104,300	-35,000 Reduced 25.02%	104,869 $237,000
Q3 2022 Nov 14, 2022	BUY	$1.76 - $4.94 $121,545 - $341,156	69,060 Added 97.53%	139,869 $270,000
Q2 2022 Aug 15, 2022	BUY	$2.47 - $6.77 $174,898 - $479,376	70,809 New	70,809 $263,000

117

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.